// App-Quantinova.ai

738 : Elvitegravir Reduces Monocyte Activation and Vascular Inflammation More Than Efavirenz

Researchers

Presenter

  • Corrilynn O. Hileman

Principal Investigators

  • Bruce Kinley

  • Valeska Scharen-Guivel

  • Kathy Melbourne

  • Javier Szwarcberg

  • Janet Robinson

  • Michael M Lederman

  • Grace A. McComsey

Medical Centers

  • Infectious Diseases, Case Western Reserve University, Cleveland, OH, United States

  • Foster City, CA, United States

Locations

  • United States

Companies

  • Gilead Sciences, Inc

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Monocyte

  • Enzyme lipoprotein-associated phospholipase A2

  • High sensitivity C-reactive protein

  • HIV 1-RNA

  • Interleukin 6

Drug/Treatment

  • elvitegravir / cobicistat / emtricitabine / tenofovir

  • Efavirenz / Emtricitabine / Tenofovir

  • Elvitegravir

  • Cobicistat

  • Efavirenz

  • Tenofovir disoproxil fumarate

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved